ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Matricelf Ltd. | MTLF | Israel | $27.07M | 946 |
| Evaxion A/S | EVAX | United States of America | $31.03M | 384 |
| Actinium Pharmaceuticals, Inc. | ATNM | United States of America | $30.76M | 519 |
| Nasus Pharma Ltd | NSRX | United States of America | $30.68M | 97 |
| Apollomics Inc. | APLM | United States of America | $40.67M | 178 |
| Passage BIO, Inc. | PASG | United States of America | $15.45M | 471 |
| SAREUM HOLDINGS PLC | SAR | United Kingdom | $39.75M | 371 |
| Molecure S.A. | MOC | Poland | $39.14M | 488 |
| Klaria Pharma Holding AB | KLAR | Sweden | $21.06M | 437 |
| Mendus | IMMU | Sweden | $33.25M | 462 |
| Elicera Therapeutics AB | ELIC | Sweden | $17.53M | 387 |
| Serina Therapeutics, Inc. | SER | United States of America | $27.95M | 514 |
| IGC Pharma, Inc. | IGC | United States of America | $28.39M | 793 |
| NOMAD POWER SOLUTIONS, INC. | NMAD | United States of America | $125.36M | 515 |
| CERENOME, INC. | CNSY | United States of America | $37.24M | 1,428 |
| Tvardi Therapeutics, Inc. | TVRD | United States of America | $18.95M | 841 |
| LeonaBio, Inc. | LONA | United States of America | $26.62M | 465 |
| Anebulo Pharmaceuticals, Inc. | ANEB | United States of America | $13.70M | 198 |
| Dare Bioscience, Inc. | DARE | United States of America | $26.50M | 799 |
| EXICURE, INC. | XCUR | United States of America | $10.71M | 528 |
| Boundless Bio, Inc. | BOLD | United States of America | $31.90M | 165 |
| NeuroSense Therapeutics Ltd. | NRSN | Israel | $28.46M | 309 |
| Sprint Bioscience | SPRINT | Sweden | $25.29M | 597 |
| Jasper Therapeutics, Inc. | JSPR | United States of America | $23.75M | 497 |
| Xintela AB | XINT | Sweden | $17.97M | 522 |
| Tempest Therapeutics, Inc. | TPST | United States of America | $24.81M | 1,037 |
| ABVC BIOPHARMA, INC. | ABVC | United States of America | $31.59M | 795 |
| Lexaria Bioscience Corp. | LEXX | United States of America | $15.79M | 1,071 |
| CDT Equity Inc. | CDT | United States of America | $5.59M | 347 |
| Senti Biosciences Holdings, Inc. | SNTI | United States of America | $24.04M | 368 |
| GenSight Biologics S.A. | SIGHT | France | $24.03M | 712 |
| Vistagen Therapeutics, Inc. | VTGN | United States of America | $22.31M | 842 |
| Apimeds Pharmaceuticals US, Inc. | APUS | United States of America | $2.36M | 126 |
| Initiator Pharma A/S | INIT | Denmark | $20.22M | 609 |
| Cyclerion Therapeutics, Inc. | CYCN | United States of America | $13.08M | 386 |
| Neuphoria Therapeutics Inc. | NEUP | United States of America | $18.27M | 418 |
| Skye Bioscience, Inc. | SKYE | United States of America | $24.72M | 653 |
| Lantern Pharma Inc. | LTRN | United States of America | $47.72M | 307 |
| Barinthus Biotherapeutics plc. | BRNS | United Kingdom | $22.10M | 284 |
| Alzinova AB | ALZ | Sweden | $21.75M | 845 |
| NanoGroup S.A. | NNG | Poland | $28.84M | 1,049 |
| AlzeCure Pharma | ALZCUR | Sweden | $21.28M | 656 |
| BullFrog AI Holdings, Inc. | BFRG | United States of America | $13.67M | 199 |
| Poltreg S.A. | PTG | Poland | $20.82M | 374 |
| Aelis Farma | AELIS | France | $20.51M | 184 |
| Isofol Medical | ISOFOL | Sweden | $20.25M | 244 |
| Yarrow Bioscience, Inc. | YARW | United States of America | $21.88M | 703 |
| NANOVIRICIDES, INC. | NNVC | United States of America | $30.57M | 549 |
| EXACT Therapeutics AS | EXTX | Norway | $9.80M | 285 |
| BerGenBio | BGBIO | Norway | $19.16M | 1,009 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.